All In Biotech

Drug Trial Radar · NCT00112918

Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma: The AVANT Study

Last checked: Nov 19, 2026Latest source record: Aug 27, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,451 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,451

Actual

Start

Dec 2004

Primary completion

Jun 2010

Study completion Jun 2012

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
Jun 3, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab (Bv) may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer in adjuvant setting. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens with or without bevacizumab to compare how well they work in treating patients who have undergone surgery for high risk stage II or stage III colon cancer.

Conditions

  • Colorectal Cancer

Interventions

  • BevacizumabBiological

    Administered as an intravenous infusion over 30 - 90 minutes.

  • CapecitabineDrug

    Film-coated tablets

  • 5-Fluorouracil (5-FU)Drug

    Administered as either a bolus injection or continuous intravenous infusion over 22 hours.

  • Leucovorin calciumDrug

    Administered as a 200 mg/m\^2 infusion over 2 hours.

  • OxaliplatinDrug

    Administered as an intravenous infusion over 2 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free Survival in Stage III Cancer Patients - Time to EventTime frame: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).
  2. Disease-free Survival in Stage III Cancer Patients - Number of EventsTime frame: From first patient randomized until the data cut-off date of 30 June 2010 (36 months after the last patient randomized).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jonsson Comprehensive Cancer Center at UCLA

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.